These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 23481658)

  • 21. Comparative in vitro activities of daptomycin, linezolid, and quinupristin/dalfopristin against Gram-positive bacterial isolates from a large cancer center.
    Smith PF; Booker BM; Ogundele AB; Kelchin P
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):255-9. PubMed ID: 15935606
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro activity of telavancin compared with vancomycin and linezolid against Gram-positive organisms isolated from cancer patients.
    Rolston K; Wang W; Nesher L; Coyle E; Shelburne S; Prince RA
    J Antibiot (Tokyo); 2014 Jul; 67(7):505-9. PubMed ID: 24824818
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activity of daptomycin against multi-resistant Gram-positive bacteria including enterococci and Staphylococcus aureus resistant to linezolid.
    Johnson AP; Mushtaq S; Warner M; Livermore DM
    Int J Antimicrob Agents; 2004 Oct; 24(4):315-9. PubMed ID: 15380254
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Comparative in vitro activity of daptomycin against gram-positive microorganisms: SENTRY surveillance program, Spain (2002-2006)].
    Loza E; Morosini MI; Pascual A; Tubau F; Alcalá J; Liñares J; Hernández-Bello JR; Baquero F; Perea E; Martín R; Jones RN; Cantón R;
    Enferm Infecc Microbiol Clin; 2008 Oct; 26(8):489-94. PubMed ID: 19094861
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antimicrobial activity of daptomycin tested against gram-positive strains collected in European hospitals: results from 7 years of resistance surveillance (2003-2009).
    Sader HS; Farrell DJ; Jones RN
    J Chemother; 2011 Aug; 23(4):200-6. PubMed ID: 21803696
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Spectrum of gram-positive bacteraemia and in vitro activities of daptomycin, linezolid and vancomycin against organisms isolated from cancer patients.
    Rolston KV; Kapadia M; Tarrand J; Coyle E; Prince RA
    Int J Antimicrob Agents; 2013 Jun; 41(6):516-20. PubMed ID: 23481658
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro activity of daptomycin against clinical isolates with reduced susceptibilities to linezolid and quinupristin/dalfopristin.
    Anastasiou DM; Thorne GM; Luperchio SA; Alder JD
    Int J Antimicrob Agents; 2006 Nov; 28(5):385-8. PubMed ID: 17046205
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Update of antimicrobial resistance in Gram-positive microorganisms].
    Cercenado E
    Med Clin (Barc); 2010 Dec; 135 Suppl 3():10-5. PubMed ID: 21477699
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New drugs for Gram-positive uropathogens.
    Wagenlehner FM; Naber KG
    Int J Antimicrob Agents; 2004 Sep; 24 Suppl 1():S39-43. PubMed ID: 15364305
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Role of daptomycin in the empirical and directed therapy of infections caused by Gram-positive bacteria in the critically ill patient].
    Garnacho-Montero J; Amaya-Villar R; Gómez-Grande ML; Jerez V; Lorente-Ramos L; Loza A; Martínez A; Pozo JC; Sierra R; Pomares J; de la Torre MV; Ortiz C
    Rev Esp Quimioter; 2011 Mar; 24(1):13-24. PubMed ID: 21412665
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oxazolidinone antibiotics.
    Diekema DJ; Jones RN
    Lancet; 2001 Dec; 358(9297):1975-82. PubMed ID: 11747939
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vancomycin-resistant enterococcal bacteremia pharmacotherapy.
    Patel R; Gallagher JC
    Ann Pharmacother; 2015 Jan; 49(1):69-85. PubMed ID: 25352037
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The oxazolidinones as a new family of antimicrobial agent.
    Marchese A; Schito GC
    Clin Microbiol Infect; 2001; 7 Suppl 4():66-74. PubMed ID: 11688536
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Epidemiology of the infection by resistant Gram-positive microorganisms].
    Cercenado E
    Rev Esp Quimioter; 2016 Sep; 29 Suppl 1():6-9. PubMed ID: 27608305
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Role of linezolid in antimicrobial therapy].
    Carmona PM; Romá E; Monte E; García J; Gobernado M
    Enferm Infecc Microbiol Clin; 2003 Jan; 21(1):30-41. PubMed ID: 12550042
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Daptomycin: pharmacological characteristics and its role in the treatment of gram positive infections].
    Araos R; García P; Chanqueo L; Labarca J
    Rev Chilena Infectol; 2012 Apr; 29(2):127-31. PubMed ID: 22689024
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Management of gram-positive bacterial infections in patients with cancer.
    Kosmidis CI; Chandrasekar PH
    Leuk Lymphoma; 2012 Jan; 53(1):8-18. PubMed ID: 21740298
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mechanisms of action of newer antibiotics for Gram-positive pathogens.
    Hancock RE
    Lancet Infect Dis; 2005 Apr; 5(4):209-18. PubMed ID: 15792738
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Future trends in the treatment of serious Gram-positive infections.
    Metzger R; Bonatti H; Sawyer R
    Drugs Today (Barc); 2009 Jan; 45(1):33-45. PubMed ID: 19271030
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Enterococci With Special Resistance Patterns - Epidemiology, Hygiene and Therapy].
    Mischnik A; Werner G; Bender J; Mutters NT
    Dtsch Med Wochenschr; 2019 Apr; 144(8):553-560. PubMed ID: 30986864
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.